

Apixaban versus enoxaparin for thromboprophylaxis at randomised double-blind trial

Lancet, The

375, 807-815

DOI: [10.1016/s0140-6736\(09\)62125-5](https://doi.org/10.1016/s0140-6736(09)62125-5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The new oral anticoagulants, do they change the benefit vs. risk for thromboprophylaxis in association to ambulatory surgery?. <i>Current Opinion in Anaesthesiology</i> , 2010, 23, 722-725.	0.9	4
2	New Anticoagulants for the Prevention of Thromboembolism. <i>Current Pharmaceutical Design</i> , 2010, 16, 3472-3474.	0.9	3
3	Treatment options in heparin-induced thrombocytopenia. <i>Current Opinion in Hematology</i> , 2010, 17, 424-431.	1.2	11
4	Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1263-1271.	1.8	326
5	Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: Comparison with direct inhibitors of factor VIIa, XIa and thrombin. <i>Thrombosis and Haemostasis</i> , 2010, 104, 302-310.	1.8	63
8	Nuovi farmaci antitrombotici in chirurgia ortopedica: dagli studi clinici all'uso nella pratica quotidiana. <i>Archivio Di Ortopedia E Reumatologia</i> , 2010, 121, 32-35.	0.0	0
10	Consenso intersocietario sulla profilassi antitrombotica in chirurgia protesica dell'anca e del ginocchio e nelle fratture del collo femorale. <i>LO SCALPELLO-OTODI Educational</i> , 2010, 24, 206-211.	0.1	3
11	Regional anaesthesia and anticoagulation. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2010, 24, 121-131.	1.7	22
12	A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1966-1975.	1.9	68
13	New aspects on treatment modalities for thromboembolic episodes. <i>Journal of Internal Medicine</i> , 2010, 268, 109-119.	2.7	3
14	Improve the results of phase II trials of thromboprophylaxis with the new oral anticoagulant drugs. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1083-1084.	1.8	3
15	Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2010, 104, 976-983.	1.8	55
16	New Oral Anticoagulants for Thromboprophylaxis after Elective Total Hip and Knee Arthroplasty. <i>Thrombosis</i> , 2010, 2010, 1-9.	1.4	1
17	Thromboprophylaxis in Orthopaedic Surgery: A Clinical Review. <i>Journal of Perioperative Practice</i> , 2010, 20, 358-362.	0.3	7
18	Emerging antithrombotic agents for thromboprophylaxis, clinical potential and patient considerations. <i>Journal of Blood Medicine</i> , 2010, 1, 123.	0.7	3
19	Emerging anticoagulants for venous thromboembolism prevention. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, S17-S25.	0.5	6
20	New oral anticoagulant drugs in cardiovascular disease. <i>Thrombosis and Haemostasis</i> , 2010, 104, 49-60.	1.8	218
21	New Anticoagulants. <i>Circulation</i> , 2010, 121, 1523-1532.	1.6	262

#	ARTICLE	IF	CITATIONS
22	Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement. <i>New England Journal of Medicine</i> , 2010, 363, 2487-2498.	13.9	691
23	Warfarin Versus New Agents: Interpreting the Data. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 221-228.	0.9	38
24	Brain Metastases. <i>Seminars in Neurology</i> , 2010, 30, 217-235.	0.5	53
25	Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2010, 56, 2067-2076.	1.2	67
26	Clinical Pharmacology of Direct and Indirect Factor Xa Inhibitors. <i>Drugs</i> , 2010, 70, 1.	4.9	33
27	Short versus extended thromboprophylaxis after total knee arthroplasty: A randomized comparison. <i>Thrombosis Research</i> , 2010, 126, e298-e304.	0.8	25
28	Advances in oral anticoagulants: focus on dabigatran etexilate. <i>Expert Review of Clinical Pharmacology</i> , 2010, 3, 727-737.	1.3	2
29	Potential of new anticoagulants in patients with cancer. <i>Thrombosis Research</i> , 2010, 125, S30-S35.	0.8	14
30	Apixaban to prevent venous thromboembolism after knee replacement. <i>Lancet, The</i> , 2010, 375, 779-780.	6.3	2
31	New antithrombotic agents—insights from clinical trials. <i>Nature Reviews Cardiology</i> , 2010, 7, 498-509.	6.1	45
32	Novel anticoagulants: a discussion of clinical use in the treatment and prevention of venous thromboembolism. <i>Phlebology</i> , 2011, 26, 3-7.	0.6	4
35	Prophylaxis for Deep Vein Thrombosis and Pulmonary Embolism in the Surgical Patient. <i>Advances in Surgery</i> , 2011, 45, 361-390.	0.6	2
37	New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: Are they really better?. <i>Thrombosis and Haemostasis</i> , 2011, 106, 45-57.	1.8	20
38	Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. <i>Current Medical Research and Opinion</i> , 2011, 27, 2123-2131.	0.9	4
39	Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. <i>Thrombosis and Haemostasis</i> , 2011, 105, 181-189.	1.8	25
40	Apixaban in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 364, 806-817.	13.9	2,207
41	A Benefit-Risk Assessment of Dabigatran in the Prevention of Venous Thromboembolism in Orthopaedic Surgery. <i>Drug Safety</i> , 2011, 34, 449-463.	1.4	20
42	Edoxaban. <i>Drugs</i> , 2011, 71, 1503-1526.	4.9	98

#	ARTICLE	IF	CITATIONS
43	Apixaban. <i>Drugs</i> , 2011, 71, 2079-2089.	4.9	19
44	Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients. <i>New England Journal of Medicine</i> , 2011, 365, 2167-2177.	13.9	512
45	Emerging anticoagulants. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 31-44.	1.0	8
46	Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2011, 26, 514-526.	2.5	37
47	Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2011, 365, 699-708.	13.9	918
49	Emerging options in the treatment of deep vein thrombosis and pulmonary embolism. <i>Blood Reviews</i> , 2011, 25, 215-221.	2.8	20
50	Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism. <i>Annual Review of Medicine</i> , 2011, 62, 41-57.	5.0	177
51	Does a longer duration of oral factor Xa therapy increase the risk of bleeding or transaminitis?. <i>Thrombosis Research</i> , 2011, 127, 202-209.	0.8	0
52	Future of Anticoagulant Therapy. <i>Cardiovascular Therapeutics</i> , 2011, 29, 291-300.	1.1	6
53	Cardiovascular drug therapy in the elderly: benefits and challenges. <i>Nature Reviews Cardiology</i> , 2011, 8, 13-28.	6.1	148
54	Management of Bleeding Complications in the Anticoagulated Patient. <i>Seminars in Hematology</i> , 2011, 48, 285-294.	1.8	9
55	Old and new anticoagulants. <i>Hamostaseologie</i> , 2011, 31, 21-27.	0.9	36
56	Novos anticoagulantes em cuidados intensivos. <i>Revista Brasileira De Terapia Intensiva</i> , 2011, 23, 68-77.	0.1	4
57	Venous Thromboembolism: Classification, Risk Factors, Diagnosis, and Management. <i>ISRN Hematology</i> , 2011, 2011, 1-7.	1.6	73
58	New insights on the role of direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery. <i>Thrombosis and Haemostasis</i> , 2011, 105, 571-573.	1.8	1
59	Apixaban versus enoxaparin in patients with total knee arthroplasty. <i>Thrombosis and Haemostasis</i> , 2011, 105, 245-253.	1.8	62
61	Perioperative deep vein thrombosis prevention: what works, what does not work and does it improve outcome?. <i>Current Opinion in Anaesthesiology</i> , 2011, 24, 166-170.	0.9	12
62	VTE prophylaxis after total joint arthroplasty. <i>Current Orthopaedic Practice</i> , 2011, 22, 193-197.	0.1	1

#	ARTICLE	IF	CITATIONS
63	Postoperative Enoxaparin Prevents Symptomatic Venous Thromboembolism in High-Risk Plastic Surgery Patients. <i>Plastic and Reconstructive Surgery</i> , 2011, 128, 1093-1103.	0.7	170
64	Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis. <i>Blood Coagulation and Fibrinolysis</i> , 2011, 22, 720-726.	0.5	14
65	Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 495-505.	1.9	7
66	Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders. <i>Clinical Investigation</i> , 2011, 1, 725-737.	0.0	0
67	Pharmacotherapy of deep-venous thrombosis: current status and future perspective. <i>Clinical Investigation</i> , 2011, 1, 1039-1047.	0.0	0
70	Inhibitors of propagation of coagulation: factors V and X. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 563-580.	1.1	15
71	Anticoagulating obese patients in the modern era. <i>British Journal of Haematology</i> , 2011, 155, 137-149.	1.2	86
72	Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 441-449.	1.9	31
73	Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1868-1870.	1.9	16
74	The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 61-75.	21.5	247
75	Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 12-19.	1.9	81
76	How to prevent, treat, and overcome current clinical challenges of VTE. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 265-274.	1.9	20
77	Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data. , 2011, 129, 185-194.		29
78	The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. , 2011, 130, 46-58.		90
79	New and Emerging Anticoagulant Therapy for Atrial Fibrillation and Acute Coronary Syndrome. <i>Pharmacotherapy</i> , 2011, 31, 975-1016.	1.2	32
80	Novel Oral Anticoagulants and Their Role in Clinical Practice. <i>Pharmacotherapy</i> , 2011, 31, 1175-1191.	1.2	37
81	Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 7516-7521.	1.0	14
83	Prophylaxis for venous thromboembolism: guidelines translated for the clinician. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 122-132.	1.0	6

#	ARTICLE	IF	CITATIONS
84	Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 407-416.	1.0	105
85	Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 478-492.	1.0	163
86	New oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 310-320.	1.0	52
87	Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 326-343.	1.0	211
88	Italian intersociety consensus statement on antithrombotic prophylaxis in hip and knee replacement and in femoral neck fracture surgery. <i>Journal of Orthopaedics and Traumatology</i> , 2011, 12, 69-76.	1.0	21
89	New anticoagulants: pharmacology and clinical studies. <i>Wiener Medizinische Wochenschrift</i> , 2011, 161, 54-57.	0.5	5
90	Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. <i>Annals of Hematology</i> , 2011, 90, 1191-1200.	0.8	75
91	The proof for new oral anticoagulants: clinical trial evidence. <i>European Orthopaedics and Traumatology</i> , 2011, 2, 7-14.	0.1	3
92	Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2011, 36, 129-139.	0.6	78
93	Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulants. <i>Thrombosis Journal</i> , 2011, 9, 17.	0.9	20
94	Practical aspects of the oral new anticoagulants. <i>American Journal of Hematology</i> , 2011, 86, 586-590.	2.0	25
95	Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 9-25.	0.7	5
97	The multivalent activity of the tissue factor–thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 75-89.	1.5	27
98	The Adjustment of the Type I Error Rate in Noninferiority Trials with $\hat{\mu}$ -Margin Approach: Each of Two Different New Drugs is Approved with Two Independent Trials with the Same Active Control. <i>Journal of Biopharmaceutical Statistics</i> , 2011, 21, 498-510.	0.4	4
99	The new oral anticoagulants. <i>Clinical Medicine</i> , 2011, 11, 467-469.	0.8	4
100	The Role of Apixaban for Venous and Arterial Thromboembolic Disease. <i>Annals of Pharmacotherapy</i> , 2011, 45, 1262-1283.	0.9	16
101	Efficacy and safety of novel anticoagulants compared with established agents. <i>Therapeutic Advances in Hematology</i> , 2011, 2, 175-195.	1.1	13
102	Assessment of HIT Antibody Complex in Hip Fracture Patients Receiving Enoxaparin or Unfractionated Heparin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, 567-571.	0.7	0

#	ARTICLE	IF	CITATIONS
103	Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises. Expert Opinion on Emerging Drugs, 2011, 16, 203-233.	1.0	1
104	Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. European Heart Journal, 2011, 32, 1968-1976.	1.0	61
105	Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ, The, 2012, 344, e3675-e3675.	3.0	204
106	Case History. Annual Reports in Medicinal Chemistry, 2012, 47, 123-141.	0.5	5
107	Antithrombotic Therapy. , 2012, , 171-177.		0
108	Conflict of Interest in the Assessment of Thromboprophylaxis After Total Joint Arthroplasty. Journal of Bone and Joint Surgery - Series A, 2012, 94, 27-33.	1.4	20
109	Oral Direct Factor Xa Inhibitors Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in Patients Undergoing Total Hip or Knee Replacement. Annals of Internal Medicine, 2012, 156, 710.	2.0	80
110	Newer Anticoagulants in Cardiovascular Disease. Cardiology in Review, 2012, 20, 209-221.	0.6	24
111	Oral Factor Xa and Direct Thrombin Inhibitors. Journal of Burn Care and Research, 2012, 33, 453-461.	0.2	3
113	New Oral Anticoagulants. Clinical Pulmonary Medicine, 2012, 19, 137-142.	0.3	0
114	Thromboprophylaxis in Surgical and Medical Patients. Seminars in Respiratory and Critical Care Medicine, 2012, 33, 163-175.	0.8	22
115	Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. Thrombosis and Haemostasis, 2012, 107, 1027-1034.	1.8	25
116	Medical Management of Venous Thromboembolism: What the Interventional Radiologist Needs to Know. Seminars in Interventional Radiology, 2012, 29, 003-009.	0.3	2
118	New Options for Anticoagulation Following Total Hip Arthroplasty and Total Knee Arthroplasty: New Oral Agents on the Horizon. Hospital Practice (1995), 2012, 40, 19-26.	0.5	0
119	Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism. Therapeutic Advances in Hematology, 2012, 3, 309-323.	1.1	13
121	Apixaban for the prevention of stroke in atrial fibrillation. Expert Review of Cardiovascular Therapy, 2012, 10, 143-149.	0.6	1
122	Practical Management of Anticoagulants in Family Medicine after Orthopedic Surgery. Postgraduate Medicine, 2012, 124, 206-214.	0.9	1
123	Primary prevention of venous thromboembolism. Phlebology, 2012, 27, 23-32.	0.6	20

#	ARTICLE	IF	CITATIONS
124	Novel drugs for oral anticoagulation pharmacotherapy. Expert Review of Cardiovascular Therapy, 2012, 10, 473-488.	0.6	6
125	The Efficacy and Safety of Pharmacological Prophylaxis of Venous Thromboembolism Following Elective Knee or Hip Replacement. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 611-627.	0.7	27
126	Enoxaparin Dosing After Discharge From US Hospitals in Patients With Total Knee Replacement. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 514-518.	0.7	3
127	Prevention of Venous Thromboembolism in Total Knee and Hip Replacement. Circulation, 2012, 125, 2151-2155.	1.6	16
128	New Prospective for the Management of Low-Risk Pulmonary Embolism: Prognostic Assessment, Early Discharge, and Single-Drug Therapy with New Oral Anticoagulants. Scientifica, 2012, 2012, 1-12.	0.6	0
129	Current Status of New Anticoagulants in the Management of Venous Thromboembolism. Advances in Hematology, 2012, 2012, 1-7.	0.6	18
130	Symptomatic In-Hospital Deep Vein Thrombosis and Pulmonary Embolism Following Hip and Knee Arthroplasty Among Patients Receiving Recommended Prophylaxis. JAMA - Journal of the American Medical Association, 2012, 307, 294-303.	3.8	227
131	Venous Thromboembolism in Patients with Heart Failure: In-hospital and Chronic Use of Anti-coagulants for Prevention. Recent Patents on Cardiovascular Drug Discovery, 2012, 7, 53-58.	1.5	4
132	Apixaban: A New Player in the Anticoagulant Class. Current Drug Targets, 2012, 13, 863-875.	1.0	13
133	Prevention and Treatment of Venous Thromboembolism and Pulmonary Embolism: The Role of Novel Oral Anticoagulants. Current Clinical Pharmacology, 2012, 7, 175-194.	0.2	4
134	Newer Oral Anticoagulant Agents: A New Era in Medicine. Current Cardiology Reviews, 2012, 8, 158-165.	0.6	14
135	New Antithrombotic Drugs. Chest, 2012, 141, e120S-e151S.	0.4	284
136	Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open, 2012, 2, e001592.	0.8	69
137	The Effect of Postoperative Enoxaparin on Risk for Reoperative Hematoma. Plastic and Reconstructive Surgery, 2012, 129, 160-168.	0.7	91
138	New anticoagulants. Journal of Trauma and Acute Care Surgery, 2012, 73, 983-992.	1.1	28
139	Anticoagulant therapy. Blood Coagulation and Fibrinolysis, 2012, 23, 482-493.	0.5	25
140	Novos anticoagulantes para a profilaxia do tromboembolismo venoso em cirurgia ortopédica de grande porte: revisão sistemática de ensaios clínicos randomizados. Jornal Vascular Brasileiro, 2012, 11, 88-89.	0.1	0
141	Nuevos anticoagulantes: ¿cuántos de nuestros pacientes anticoagulados pueden tomarlos?. Revista Clínica De Medicina De Familia, 2012, 5, 151-157.	0.1	0

#	ARTICLE	IF	CITATIONS
142	Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery. <i>Thrombosis and Haemostasis</i> , 2012, 108, 903-912.	1.8	19
143	A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins. <i>Thrombosis and Haemostasis</i> , 2012, 107, 201-214.	1.8	11
144	Prevention of VTE in Orthopedic Surgery Patients. <i>Chest</i> , 2012, 141, e278S-e325S.	0.4	1,723
145	Breakthroughs in Anticoagulation: Advent of the Oral Direct Factor Xa Inhibitors. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2012, 26, 740-745.	0.6	11
146	Forty Years in Academic Cardiology. <i>Cardiology in Review</i> , 2012, 20, 265-267.	0.6	0
147	Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes?. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2053-2060.	1.9	23
148	New oral anticoagulants and venous thromboembolic disease. <i>Sang Thrombose Vaisseaux</i> , 2012, 24, 133-142.	0.1	0
149	The promise of novel direct oral anticoagulants. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 351-360.	0.7	22
150	Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement. <i>Journal of Bone and Joint Surgery: British Volume</i> , 2012, 94-B, 257-264.	3.4	88
151	A New Generation of Oral Direct Anticoagulants. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 569-574.	1.1	31
152	Performance of New Anticoagulants for Thromboprophylaxis in Patients Undergoing Hip and Knee Replacement Surgery. <i>Pharmacotherapy</i> , 2012, 32, 1036-1048.	1.2	4
154	Thromboprophylaxis in major knee and hip replacement surgery: a review. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 518-525.	1.0	7
155	Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention. <i>Drug Discovery Today</i> , 2012, 17, 296-309.	3.2	59
156	Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement. <i>Revista Española De Cirugía Ortopédica Y Traumatología</i> , 2012, 56, 459-470.	0.1	1
157	Novel oral anticoagulants - key messages for the angiologist. <i>Vasa - European Journal of Vascular Medicine</i> , 2012, 41, 177-191.	0.6	11
164	Apixaban: A novel oral inhibitor of factor Xa. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 1113-1126.	0.5	30
165	Current anticoagulant safety. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 401-413.	1.0	5
166	Use of anticoagulants in elderly patients. <i>Thrombosis Research</i> , 2012, 129, 107-115.	0.8	57

#	ARTICLE	IF	CITATIONS
167	Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: A review of the literature. <i>Thrombosis Research</i> , 2012, 129, 392-400.	0.8	56
168	Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for thromboprophylaxis after total knee or hip arthroplasty: Pool-analysis of phase III randomized clinical trials. <i>Thrombosis Research</i> , 2012, 130, 183-191.	0.8	79
169	Oral Direct Factor Xa Inhibitors. <i>Circulation Research</i> , 2012, 111, 1069-1078.	2.0	92
170	Apixaban and Rivaroxaban Safety After Hip and Knee Arthroplasty. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2012, 17, 266-276.	1.0	20
171	Apixaban. <i>Drugs</i> , 2012, 72, 1271-1291.	4.9	16
172	Novel Oral Anticoagulation in Management of Venous Thromboembolism, Atrial Fibrillation, and Acute Coronary Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 476-486.	0.7	1
173	Improving prevention and treatment of venous thromboembolism: clinical trial results. <i>Journal of Medical Economics</i> , 2012, 15, 611-622.	1.0	6
174	Safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of R1663, an oral factor Xa inhibitor, in healthy young subjects coupled with exploration of influence of gender and age. <i>Thrombosis and Haemostasis</i> , 2012, 108, 54-64.	1.8	2
175	A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. <i>Thrombosis and Haemostasis</i> , 2012, 107, 916-924.	1.8	52
176	Darexaban (YM150) prevents venous thromboembolism in Japanese patients undergoing major abdominal surgery: Phase III randomized, mechanical prophylaxis-controlled, open-label study. <i>Thrombosis Research</i> , 2012, 130, e52-e59.	0.8	18
177	Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2012, 113, 431-441.	0.2	70
179	Should deep venous thrombosis prophylaxis be used in fast-track hip and knee replacement?. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2012, 83, 105-106.	1.2	16
180	Newer Anticoagulants in Critically Ill Patients. <i>Critical Care Clinics</i> , 2012, 28, 427-451.	1.0	7
181	A new approach with anticoagulant development: tailoring anticoagulant therapy with dabigatran etexilate according to patient risk. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 217-226.	0.9	8
182	Peripheral Venous Disease. , 2012, , 499-506.		0
183	Venous Thromboembolism in Orthopaedic Surgery. , 0, , .		0
184	New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders. <i>Vascular Health and Risk Management</i> , 2012, 8, 45.	1.0	12
186	Venous thromboembolism (VTE) prevention in orthopedics: facts, controversies, and evolving management. <i>Orthopedic Research and Reviews</i> , 2012, , 77.	0.7	0

#	ARTICLE	IF	CITATIONS
187	36 Antikoagulanzen. , 2012, , .		0
188	Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery. <i>Thrombosis and Haemostasis</i> , 2012, 108, 887-895.	1.8	15
189	Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery. <i>Therapeutics and Clinical Risk Management</i> , 2012, 8, 139.	0.9	6
190	Management of heparin-induced thrombocytopenia. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 987-1006.	0.9	11
191	Old Versus New Oral Anticoagulants: Focus on Pharmacology. <i>Annual Review of Pharmacology and Toxicology</i> , 2012, 52, 79-99.	4.2	71
192	Novel Anticoagulants for Atrial Fibrillation. <i>Angiology</i> , 2012, 63, 164-170.	0.8	13
193	Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 208-213.	1.0	21
194	Apixaban: an Oral Direct Factor-Xa Inhibitor. <i>Advances in Therapy</i> , 2012, 29, 187-201.	1.3	23
195	Rivaroxaban for the prevention and treatment of venous thromboembolism. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 33-38.	1.0	3
196	A randomized phase III trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 807-814.	1.9	170
197	Venous thromboembolism and cancer. <i>ANZ Journal of Surgery</i> , 2012, 82, 294-298.	0.3	7
198	Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. <i>Thrombosis Journal</i> , 2013, 11, 10.	0.9	141
199	Inflammatory Response in Cardiovascular Surgery. , 2013, , .		2
200	New Oral Anticoagulants: Great Promise for Therapeutic Advance but Great Knowledge Gaps Remain to Be Filled. <i>Cardiology</i> , 2013, 126, 41-49.	0.6	3
201	Novel Anticoagulant Use for Venous Thromboembolism: A 2013 Update. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013, 15, 164-172.	0.4	2
202	New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 163-169.	0.7	9
203	Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 171-182.	0.7	20
205	Prevention of Venous Thromboembolism in Patients with Hemorrhagic Stroke. <i>Topics in Stroke Rehabilitation</i> , 2013, 20, 108-115.	1.0	5

#	ARTICLE	IF	CITATIONS
206	New oral anticoagulants: prevention of VTE in phase III studies in total joint replacement surgery and the hospitalized medically-ill patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 141-148.	1.0	3
207	Stroke Prevention in Atrial Fibrillation. <i>Current Emergency and Hospital Medicine Reports</i> , 2013, 1, 98-104.	0.6	0
208	Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients. <i>Thrombosis Research</i> , 2013, 131, S67-S70.	0.8	4
210	Handbook of Oral Anticoagulation. , 2013, , .		1
211	Evaluating the efficacy and safety of apixaban, a new oral anticoagulant, using Bayesian meta-analysis. <i>International Journal of Hematology</i> , 2013, 98, 390-397.	0.7	4
212	The new oral anticoagulants in atrial fibrillation: Once daily or twice daily?. <i>Vascular Pharmacology</i> , 2013, 59, 53-62.	1.0	23
213	Assessment of Anticoagulation Intensity and Management of Bleeding With Old and New Oral Anticoagulants. <i>Canadian Journal of Cardiology</i> , 2013, 29, S34-S44.	0.8	40
214	New oral anticoagulants and regional anaesthesia. <i>British Journal of Anaesthesia</i> , 2013, 111, i96-i113.	1.5	72
216	Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. <i>International Journal of Cardiology</i> , 2013, 168, 4228-4233.	0.8	96
217	The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature. <i>Thrombosis Journal</i> , 2013, 11, 18.	0.9	19
218	Consenso intersocietario sulla profilassi antitrombotica in chirurgia protesica dell'anca e del ginocchio e nelle fratture del collo femorale: aggiornamento 2013. <i>LO SCALPELLO-OTODI Educational</i> , 2013, 27, 161-169.	0.1	0
219	Practical management of new oral anticoagulants after total hip or total knee arthroplasty. <i>Musculoskeletal Surgery</i> , 2013, 97, 189-197.	0.7	11
220	Nuevos anticoagulantes frente a anticoagulantes clásicos: ventajas e inconvenientes. <i>Semergen</i> , 2013, 39, 10-16.	0.2	8
221	Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 817-828.	0.6	1
224	Pharmacologic prevention of venous thromboembolism in obese patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 247-257.	1.0	13
225	Acute management of bleeding in patients on novel oral anticoagulants. <i>European Heart Journal</i> , 2013, 34, 489-498.	1.0	152
226	Approaches to the Prophylaxis and Treatment of Venous and Cardiac Thromboembolic Disease. , 2013, , 175-237.		0
227	The Evolution of Oral Anticoagulant Therapy. <i>Primary Care - Clinics in Office Practice</i> , 2013, 40, 109-134.	0.7	6

#	ARTICLE	IF	CITATIONS
228	Influence des nouveaux anticoagulants sur les examens de la coagulation IntÃ©rÃ©t en clinique. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2013, 2013, 21-27.	0.0	2
229	New Oral Anticoagulants. Hospital Medicine Clinics, 2013, 2, e456-e471.	0.2	0
230	Haemostatic challenges in the cancer patient: Focus on the perioperative period. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2013, 27, 493-511.	1.7	5
231	SECOT consensus on thromboembolisms in knee and hip replacement surgery. Revista EspaÃ±ola De CirugÃ­a OrtopÃ©dica Y TraumatologÃ­a, 2013, 57, 150-159.	0.1	0
232	Apixaban and Rivaroxaban Decrease Deep Venous Thrombosis But Not Other Complications After Total Hip and Total Knee Arthroplasty. Journal of Arthroplasty, 2013, 28, 1477-1481.	1.5	35
233	Nuevos anticoagulantes orales y su papel en la prÃ¡ctica clÃ­nica. Revista Espanola De Cardiologia Suplementos, 2013, 13, 33-41.	0.2	12
235	Venous Thromboembolism Prophylaxis in Total Knee Arthroplasty and Total Hip Arthroplasty. Hospital Medicine Clinics, 2013, 2, e91-e102.	0.2	0
236	Thrombin inhibitors: surgical considerations and pharmacology. ANZ Journal of Surgery, 2013, 83, 215-221.	0.3	8
237	Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. Journal of Thrombosis and Haemostasis, 2013, 11, 245-252.	1.9	109
238	Implications of new anticoagulants in primary practice. International Journal of Clinical Practice, 2013, 67, 139-156.	0.8	17
239	Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. British Journal of Clinical Pharmacology, 2013, 75, 476-487.	1.1	298
240	New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding: A Systematic Review and Meta-analysis. Gastroenterology, 2013, 145, 105-112.e15.	0.6	347
241	Prevention of VTE in patients having major orthopedic surgery. Journal of Thrombosis and Thrombolysis, 2013, 35, 359-367.	1.0	26
242	Pulmonary Embolism and Deep Vein Thrombosis. , 2013, , 580-595.		1
243	Assessing bleeding risk in patients taking anticoagulants. Journal of Thrombosis and Thrombolysis, 2013, 35, 312-319.	1.0	165
244	Moving Toward a More Ideal Anticoagulant. Chest, 2013, 143, 1106-1116.	0.4	28
245	Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. European Journal of Clinical Pharmacology, 2013, 69, 1617-1633.	0.8	81
246	The New Oral Anticoagulants in Clinical Practice. Mayo Clinic Proceedings, 2013, 88, 495-511.	1.4	93

#	ARTICLE	IF	CITATIONS
247	Anticoagulation; New Pharmacologic Methods to Prevent Venous Thromboembolism in Older Adults: A Meta-Analysis. <i>Annals of Pharmacotherapy</i> , 2013, 47, 605-616.	0.9	3
248	Use of New Oral Anticoagulants in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2013, 15, 331.	2.1	48
249	The Cost-Effectiveness of Oral Direct Factor Xa Inhibitors Compared with Low-Molecular-Weight Heparin for the Prevention of Venous Thromboembolism Prophylaxis in Total Hip or Knee Replacement Surgery. <i>Pharmacotherapy</i> , 2013, 33, 1333-1340.	1.2	26
250	Transitions of care in anticoagulated patients. <i>Journal of Multidisciplinary Healthcare</i> , 2013, 6, 215.	1.1	18
251	Systematic Review of Randomized Controlled Trials of New Anticoagulants for Venous Thromboembolism Prophylaxis in Major Orthopedic Surgeries, Compared With Enoxaparin. <i>Annals of Vascular Surgery</i> , 2013, 27, 355-369.	0.4	31
252	The safety and efficacy of apixaban: where do we stand in 2013?. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 559-567.	1.0	3
253	Antithrombotic Agents. , 2013, , 477-495.		2
254	Oral anticoagulants in the management of venous thromboembolism. <i>Nature Reviews Cardiology</i> , 2013, 10, 397-409.	6.1	14
255	Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 908-916.	1.1	234
256	Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. <i>Clinical Research in Cardiology</i> , 2013, 102, 399-412.	1.5	179
257	Thromboprophylaxis only during hospitalisation in fast-track hip and knee arthroplasty, a prospective cohort study. <i>BMJ Open</i> , 2013, 3, e003965.	0.8	91
258	Pharmacoeconomic implications of thromboprophylaxis with new oral anticoagulants after total hip or knee replacement in the USA. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 525-534.	0.9	2
259	A Canadian Study of the Cost-Effectiveness of Apixaban Compared With Enoxaparin for Post-Surgical Venous Thromboembolism Prevention. <i>Postgraduate Medicine</i> , 2013, 125, 141-153.	0.9	23
260	Novel oral anticoagulants for the prevention and treatment of thromboembolism. <i>Future Cardiology</i> , 2013, 9, 849-861.	0.5	3
261	The Novel Oral Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 117-126.	1.5	28
262	Apixaban. <i>Hospital Pharmacy</i> , 2013, 48, 494-511.	0.4	10
263	Treatment with novel oral anticoagulants. <i>Current Opinion in Hematology</i> , 2013, 20, 430-436.	1.2	27
264	Apixaban. <i>Cardiology in Review</i> , 2013, 21, 207-212.	0.6	1

#	ARTICLE	IF	CITATIONS
265	Transitions of Care in Patients Receiving Oral Anticoagulants. <i>Journal of Cardiovascular Nursing</i> , 2013, 28, 54-65.	0.6	4
266	Managing New Oral Anticoagulants in the Intensive Care Unit. <i>Critical Care Nursing Quarterly</i> , 2013, 36, 390-399.	0.4	1
267	New oral therapies for the prevention and treatment of venous thromboembolism. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 113-125.	0.5	7
268	Orthopedic Surgery and Trauma. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013, 19, 141-160.	0.7	1
269	Novel Oral Anticoagulants: A Review of New Agents. <i>Postgraduate Medicine</i> , 2013, 125, 103-114.	0.9	19
270	The challenges of determining noninferiority margins: a case study of noninferiority randomized controlled trials of novel oral anticoagulants. <i>Cmaj</i> , 2013, 185, 222-227.	0.9	25
272	An Updated Review of Target-Specific Oral Anticoagulants Used in Stroke Prevention in Atrial Fibrillation, Venous Thromboembolic Disease, and Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2013, 2, e000136.	1.6	24
273	Prophylaxis and treatment of venous thromboembolism in the critically ill. <i>International Journal of Critical Illness and Injury Science</i> , 2013, 3, 143.	0.2	16
274	Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 778-782.	1.9	10
275	Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 776-786.	1.1	251
276	Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 444-451.	1.9	31
277	Outpatient Anticoagulant Therapy. , 2013, , 698-716.		1
278	Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty. <i>Journal of Bone and Joint Surgery - Series A</i> , 2013, 95, 1801-1811.	1.4	81
279	The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. <i>Expert Review of Hematology</i> , 2013, 6, 677-695.	1.0	36
280	Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting. <i>Anesthesiology</i> , 2013, 118, 1466-1474.	1.3	158
281	Management of severe perioperative bleeding. <i>European Journal of Anaesthesiology</i> , 2013, 30, 270-382.	0.7	740
282	Relative Effects of Two Different Enoxaparin Regimens as Comparators Against Newer Oral Anticoagulants. <i>Chest</i> , 2013, 144, 593-600.	0.4	16
283	The perioperative management of new direct oral anticoagulants: a question without answers. <i>Thrombosis and Haemostasis</i> , 2013, 110, 515-522.	1.8	76

#	ARTICLE	IF	CITATIONS
284	Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies. <i>Thrombosis and Haemostasis</i> , 2013, 110, 205-212.	1.8	155
285	Prophylaxis for deep venous thrombosis and pulmonary embolism in surgery. , 0, , 234-251.		0
286	Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. <i>Clinical Pharmacology: Advances and Applications</i> , 2013, 5, 59.	0.8	20
287	Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. <i>Vascular Health and Risk Management</i> , 2013, 9, 207.	1.0	26
288	A new paradigm shift in antithrombotic therapy. <i>Frontiers in Pharmacology</i> , 2013, 4, 133.	1.6	19
289	Comparative safety and efficacy of antithrombotics in the management of venous thromboembolism after knee or hip replacement surgery: focus on rivaroxaban. <i>Clinical Pharmacology: Advances and Applications</i> , 2013, 5, 143.	0.8	3
290	The Efficacy and Safety of Rivaroxaban for Venous Thromboembolism Prophylaxis after Total Hip and Total Knee Arthroplasty. <i>Thrombosis</i> , 2013, 2013, 1-5.	1.4	12
291	Prevention and Treatment of Venous Thromboembolism with New Oral Anticoagulants: A Practical Update for Clinicians. <i>Thrombosis</i> , 2013, 2013, 1-10.	1.4	11
292	Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects. <i>Clinical Pharmacology: Advances and Applications</i> , 2013, 5, 177.	0.8	21
293	Deep Vein Thrombosis and Pulmonary Embolism. , 2013, , 247-261.		1
295	Do novel oral anticoagulants do better than standard therapy in the treatment of deep vein thrombosis?. <i>Hamostaseologie</i> , 2013, 33, 218-224.	0.9	3
296	A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. <i>Clinical Pharmacology: Advances and Applications</i> , 2014, 6, 179.	0.8	59
297	Thrombosis – Besieged but Poorly Understood. <i>Frontiers in Cardiovascular Medicine</i> , 2014, 1, 4.	1.1	0
298	Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence. <i>Drug Design, Development and Therapy</i> , 2014, 8, 2181.	2.0	4
299	Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides. <i>Thrombosis and Haemostasis</i> , 2014, 111, 10-13.	1.8	10
301	Darexaban for the Prevention of Venous Thromboembolism in Asian Patients Undergoing Orthopedic Surgery. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 199-211.	0.7	24
302	Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting. <i>BioMed Research International</i> , 2014, 2014, 1-16.	0.9	23
303	Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	6

#	ARTICLE	IF	CITATIONS
304	Direct oral anticoagulants: integration into clinical practice. Postgraduate Medical Journal, 2014, 90, 529-539.	0.9	15
305	Model-Based Exposure-Response Analysis of Apixaban to Quantify Bleeding Risk in Special Populations of Subjects Undergoing Orthopedic Surgery. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-9.	1.3	40
307	Direct Oral Anticoagulants. JACC: Cardiovascular Interventions, 2014, 7, 1333-1351.	1.1	81
308	Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, Versus Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty: The STARS E-3 Trial. Thrombosis Research, 2014, 134, 1198-1204.	0.8	117
309	Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thrombosis Journal, 2014, 12, 24.	0.9	45
310	Indirect comparison meta-analysis of two enoxaparin regimens in patients undergoing major orthopaedic surgery. Thrombosis and Haemostasis, 2014, 112, 503-510.	1.8	10
311	Emergent Reversal of Oral Anticoagulation. AACN Advanced Critical Care, 2014, 25, 5-12.	0.6	1
312	The new factor Xa inhibitor: Apixaban. Journal of Pharmacology and Pharmacotherapeutics, 2014, 5, 12-14.	0.2	13
313	Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation. Annals of the New York Academy of Sciences, 2014, 1329, 93-106.	1.8	24
315	The place of new oral anticoagulants in travel medicine. Travel Medicine and Infectious Disease, 2014, 12, 7-19.	1.5	4
316	Direct Oral Anticoagulants—Pharmacology, Drug Interactions, and Side Effects. Seminars in Hematology, 2014, 51, 89-97.	1.8	35
317	Direct Oral Anticoagulants in the Prevention of Venous Thromboembolism: Evidence From Major Clinical Trials. Seminars in Hematology, 2014, 51, 121-130.	1.8	9
318	Antithrombotic prophylaxis in major orthopaedic surgery: an historical overview and update of current recommendations. International Orthopaedics, 2014, 38, 169-175.	0.9	24
319	Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects. American Journal of Cardiovascular Drugs, 2014, 14, 147-154.	1.0	133
321	Evidence behind quality of care measures for venous thromboembolism and atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2014, 37, 87-96.	1.0	6
322	Apixaban for oral antithrombotic therapy: is a new era coming?. Molecular and Cellular Therapies, 2014, 2, 4.	0.2	1
323	Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. British Journal of Clinical Pharmacology, 2014, 78, 707-717.	1.1	45
324	Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. British Journal of Clinical Pharmacology, 2014, 78, 877-885.	1.1	46

#	ARTICLE	IF	CITATIONS
325	Latest developments in anticoagulant drug discovery. <i>Drug Discovery Today</i> , 2014, 19, 921-935.	3.2	6
326	Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. <i>Heart</i> , 2014, 100, 550-556.	1.2	91
327	Perioperative management of patients on new oral anticoagulants. <i>British Journal of Surgery</i> , 2014, 101, 742-749.	0.1	74
328	Recomendações da SBA para segurança na anestesia regional em uso de anticoagulantes. <i>Revista Brasileira De Anestesiologia</i> , 2014, 64, 1-15.	0.6	5
331	Pharmacology and Safety of New Oral Anticoagulants. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 443-452.	0.7	8
332	Pharmacology and Laboratory Testing of the Oral Xa Inhibitors. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 503-517.	0.7	23
333	Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor. <i>Drugs</i> , 2014, 74, 1209-1231.	4.9	84
334	Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations. <i>Postgraduate Medical Journal</i> , 2014, 90, 520-528.	0.9	31
337	Venous Thromboembolism (VTE) Prophylaxis for Hip and Knee Arthroplasty: Changing Trends. <i>Current Reviews in Musculoskeletal Medicine</i> , 2014, 7, 108-116.	1.3	32
339	Recomendaciones de SBA para la seguridad en la anestesia regional en uso de anticoagulantes. <i>Brazilian Journal of Anesthesiology (Edición En Espanol)</i> , 2014, 64, 1-15.	0.0	0
340	SBA Recommendations for regional anesthesia safety in patients taking anticoagulants. <i>Brazilian Journal of Anesthesiology (Elsevier)</i> , 2014, 64, 1-15.	0.2	6
341	Searching for Indirect Evidence and Extending the Network of Studies for Network Meta-Analysis: Case Study in Venous Thromboembolic Events Prevention Following Elective Total Knee Replacement Surgery. <i>Value in Health</i> , 2014, 17, 416-423.	0.1	10
342	Potential antidotes for reversal of old and new oral anticoagulants. <i>Thrombosis Research</i> , 2014, 133, S158-S166.	0.8	37
344	A Systematic Review and Adjusted Indirect Comparison of Oral Anticoagulants. <i>Orthopedics</i> , 2014, 37, 763-771.	0.5	5
345	How I treat target-specific oral anticoagulant-associated bleeding. <i>Blood</i> , 2014, 123, 1152-1158.	0.6	108
346	Benefit-to-harm ratio of thromboprophylaxis for patients undergoing major orthopaedic surgery. <i>Thrombosis and Haemostasis</i> , 2014, 112, 199-212.	1.8	8
348	Non-vitamin K Antagonist Oral Anticoagulants (NOACs): a View from the Laboratory. <i>British Journal of Biomedical Science</i> , 2014, 71, 158-167.	1.2	13
349	Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications. <i>Regional Anesthesia and Pain Medicine</i> , 2015, 40, 182-212.	1.1	248

#	ARTICLE	IF	CITATIONS
350	Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients. <i>Current Orthopaedic Practice</i> , 2015, 26, 299-305.	0.1	3
351	Thromboprophylaxis with apixaban and the risk of pulmonary embolism in patients undergoing knee replacement surgery. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2015, 5, 27889.	0.4	6
352	Venous Thromboembolism Prophylaxis After Total Joint Arthroplasty. <i>Orthopedics</i> , 2015, 38, 252-263.	0.5	10
353	The effect of new oral anticoagulants and extended thromboprophylaxis policy on hip and knee arthroplasty outcomes: observational study. <i>Arthroplasty Today</i> , 2015, 1, 45-50.	0.8	3
354	Management of Bleeding Complications in Patients Taking Direct Oral Anticoagulants at a Large Tertiary Academic Medical Center. <i>Current Emergency and Hospital Medicine Reports</i> , 2015, 3, 162-167.	0.6	0
355	Combination of Superficial and Deep Blocks with Rivaroxaban. <i>Pain Medicine</i> , 2015, 16, 2024-2030.	0.9	8
356	Randomized, blinded, placebo- and positive-controlled crossover study to determine the effect of multiple doses of apixaban on the QTc interval. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 549-555.	1.0	6
357	A new generation of antiplatelet and anticoagulant medication and the implications for the dental surgeon. <i>Dental Update</i> , 2015, 42, 840-854.	0.1	9
358	Lack of consistency in the relationship between asymptomatic DVT detected by venography and symptomatic VTE in thromboprophylaxis trials. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1049-1057.	1.8	26
359	Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2015, 113, 231-246.	1.8	40
360	Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty. <i>Thrombosis and Haemostasis</i> , 2015, 114, 237-244.	1.8	2
361	Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1239-1249.	1.9	51
362	Insights into direct anticoagulants. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 492-498.	0.5	1
363	Patient preferences regarding pharmacologic venous thromboembolism prophylaxis. <i>Journal of Hospital Medicine</i> , 2015, 10, 108-111.	0.7	35
364	Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in elderly elective postarthroplasty patients. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 934-939.	0.5	9
365	PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT. <i>Rational Pharmacotherapy in Cardiology</i> , 2015, 11, 287-292.	0.3	3
366	Apixaban in Venous Thromboembolism in an Era of New Oral Anticoagulants. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2015, 15, 139-147.	0.2	0
367	Titrating haemophilia B phenotypes using siRNA strategy: evidence that antithrombotic activity is separated from bleeding liability. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1300-1311.	1.8	6

#	ARTICLE	IF	CITATIONS
368	Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2015, 15, 92-96.	0.2	13
369	Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1273.	0.9	23
370	Apixaban and oral implications. <i>Journal of Clinical and Experimental Dentistry</i> , 2015, 7, e528-e534.	0.5	4
371	A comprehensive study of apixaban's degradation pathways under stress conditions using liquid chromatography coupled to multistage mass spectrometry. <i>RSC Advances</i> , 2015, 5, 35586-35597.	1.7	13
372	Timing the First Postoperative Dose of Anticoagulants. <i>Chest</i> , 2015, 148, 587-595.	0.4	15
373	VTE primary prevention, including hospitalised medical and orthopaedic surgical patients. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1216-1223.	1.8	11
374	Overview of Venous Thrombosis in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1195-1203.	0.9	20
375	Management of Bleeding Associated with New Oral Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 788-801.	1.5	17
376	The additional benefit of graduated compression stockings to pharmacologic thromboprophylaxis in the prevention of venous thromboembolism in surgical inpatients. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2015, 3, 447-455.e1.	0.9	13
377	Venous Disorders: Medical Management. , 2015, , 1009-1034.		0
378	Changing Practice of Anticoagulation: Will Target-Specific Anticoagulants Replace Warfarin?. <i>Annual Review of Medicine</i> , 2015, 66, 241-253.	5.0	19
379	Making (Anti)Sense of Factor XI in Thrombosis. <i>New England Journal of Medicine</i> , 2015, 372, 277-278.	13.9	7
380	The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders. <i>Thrombosis Research</i> , 2015, 135, 217-225.	0.8	28
381	Novel oral anticoagulants: What dermatologists need to know. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 535-540.	0.6	27
382	Meta-Analysis on Risk of Bleeding With Apixaban in Patients With Renal Impairment. <i>American Journal of Cardiology</i> , 2015, 115, 323-327.	0.7	36
383	Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban. <i>Clinical Pharmacokinetics</i> , 2015, 54, 651-662.	1.6	67
384	A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 231-239.	1.0	32
385	Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials. <i>Thrombosis Research</i> , 2015, 135, 816-822.	0.8	18

#	ARTICLE	IF	CITATIONS
386	Dosing of Target-Specific Oral Anticoagulants in Special Populations. <i>Annals of Pharmacotherapy</i> , 2015, 49, 1031-1045.	0.9	16
387	Which Patients May Benefit from Dose Adjustment of Non-Vitamin K Antagonist Oral Anticoagulants?. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 195-207.	1.5	17
388	Risk factors for venous thromboembolism of total hip arthroplasty and total knee arthroplasty: a systematic review of evidences in ten years. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 24.	0.8	62
389	Risk of Substantial Intraocular Bleeding With Novel Oral Anticoagulants. <i>JAMA Ophthalmology</i> , 2015, 133, 834.	1.4	29
390	Thromboprophylaxis with Low-Molecular-Weight Heparins: An Assessment of the Methodological Quality of Studies. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 113-132.	1.5	7
391	Using New Oral Anticoagulants in Patients Undergoing Major Orthopedic Surgery. <i>Current Rheumatology Reports</i> , 2015, 17, 25.	2.1	4
392	Venous thromboembolism: identifying patients at risk and establishing prophylaxis. <i>Current Medical Research and Opinion</i> , 2015, 31, 2297-2311.	0.9	10
393	Prevention of Venous Thromboembolism: An Evidence-Based Approach to Thromboprophylaxis. , 2015, , 123-134.		0
394	Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, doseâ€“response meta-analysis and network meta-analysis. <i>Thrombosis Research</i> , 2015, 136, 1133-1144.	0.8	55
395	Clinical Experience With Novel Oral Anticoagulants for Thromboprophylaxis After Elective Hip and Knee Arthroplasty. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 771-778.	1.1	23
396	Handbook for Venous Thromboembolism. , 2015, , .		10
397	Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors. <i>World Neurosurgery</i> , 2015, 84, 1956-1961.	0.7	78
398	Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects. <i>Clinical Therapeutics</i> , 2015, 37, 1703-1712.	1.1	30
399	Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 838-846.	1.1	130
400	Apixaban and risk of myocardial infarction: meta-analysis of randomized controlled trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 1-11.	1.0	7
402	Apixaban Versus Enoxaparin in Elective Major Orthopedic Surgery. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 115-119.	0.7	8
403	New Oral Anticoagulants: General Features and Review of Pivotal Clinical Trials. <i>The Korean Journal of Helicobacter and Upper Gastrointestinal Research</i> , 2016, 16, 178.	0.1	1
404	Use of novel oral anticoagulant agents in venous thromboembolism. <i>Cardiovascular Diagnosis and Therapy</i> , 2016, 6, 570-581.	0.7	17

#	ARTICLE	IF	CITATIONS
405	Reducing the risk of venous thromboembolism using apixaban – patient perspectives and considerations. Should more attention be given to females?. Patient Preference and Adherence, 2016, 10, 73.	0.8	1
406	Uso de los anticoagulantes orales directos en la prÁctica clÁnica. Revista Facultad De Medicina, 2016, 64, 295.	0.0	1
407	Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date. Drug, Healthcare and Patient Safety, 2016, 8, 25.	1.0	0
408	Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty. Thrombosis and Haemostasis, 2016, 115, 600-607.	1.8	28
409	Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants. Frontiers in Cardiovascular Medicine, 2016, 3, 24.	1.1	22
410	Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. Journal of Clinical Pharmacology, 2016, 56, 637-645.	1.0	141
411	Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis. Internal Medicine Journal, 2016, 46, 1030-1037.	0.5	6
412	Perioperative Management of Anticoagulation”Review of Latest Evidence. American Journal of Therapeutics, 2016, 23, e474-e484.	0.5	8
413	New oral anticoagulants: appropriateness of prescribing in real-world setting. Internal Medicine Journal, 2016, 46, 812-818.	0.5	51
415	Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol. BMJ Open, 2016, 6, e011028.	0.8	14
417	Evolving Treatments for Arterial and Venous Thrombosis. Circulation Research, 2016, 118, 1409-1424.	2.0	96
418	Update on Anticoagulation: What the Interventional Radiologist Needs to Know. Seminars in Interventional Radiology, 2016, 33, 122-131.	0.3	4
419	Use of direct oral anticoagulants with regional anesthesia in orthopedic patients. Journal of Clinical Anesthesia, 2016, 32, 224-235.	0.7	14
420	Direct oral anticoagulants and venous thromboembolism. European Respiratory Review, 2016, 25, 295-302.	3.0	27
421	An update on the pharmaceutical management of thrombosis. Expert Opinion on Pharmacotherapy, 2016, 17, 2149-2164.	0.9	7
423	Postorthopedic Surgery Joint Replacement Surgery Venous Thromboembolism Prophylaxis. Hematology/Oncology Clinics of North America, 2016, 30, 1007-1018.	0.9	5
424	Prevençã3n de la enfermedad tromboemb3lica venosa en cirugÃa. EMC - Anestesia-Reanimaci3n, 2016, 42, 1-17.	0.1	1
425	Prevenzione della tromboembolia venosa in ambiente chirurgico. EMC - Anestesia-Rianimazione, 2016, 21, 1-16.	0.1	0

#	ARTICLE	IF	CITATIONS
426	Popular naturally occurring antioxidants as potential anticoagulant drugs. <i>Chemico-Biological Interactions</i> , 2016, 257, 35-45.	1.7	25
427	The Prevention of Venous Thromboembolism in Surgical Patients. <i>Advances in Experimental Medicine and Biology</i> , 2016, 906, 1-8.	0.8	14
428	Impact of recent guideline changes on aspirin prescribing after knee arthroplasty. <i>Journal of Orthopaedic Surgery and Research</i> , 2016, 11, 123.	0.9	26
429	A Review on the Reversal of the Old and New Anticoagulants. <i>Advanced Emergency Nursing Journal</i> , 2016, 38, 279-294.	0.2	1
430	Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults. <i>Clinical Therapeutics</i> , 2016, 38, 1674-1685.e1.	1.1	32
431	Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 628-636.	1.0	224
432	Review of the Target-Specific Oral Anticoagulants in Development for the Treatment and Prevention of Venous Thromboembolism. <i>Journal of Pharmacy Practice</i> , 2016, 29, 392-405.	0.5	2
433	Pharmacological thromboprophylaxis and total hip or knee replacement. <i>British Journal of Nursing</i> , 2016, 25, 45-53.	0.3	4
434	Safety, pharmacokinetics, and pharmacodynamics of PD 0348292, an oral, direct factor Xa inhibitor, after single and multiple dosings in healthy subjects. <i>Clinical Pharmacology in Drug Development</i> , 2016, 5, 13-26.	0.8	3
435	Primary Joint Arthroplasty Surgery: Is the Risk of Major Bleeding Higher in Elderly Patients? A Retrospective Cohort Study. <i>Journal of Arthroplasty</i> , 2016, 31, 2264-2268.	1.5	13
436	Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 042-054.	1.5	18
437	Perioperative Approach to Anticoagulants and Hematologic Disorders. <i>Anesthesiology Clinics</i> , 2016, 34, 101-125.	0.6	6
438	Safety and Efficacy of Novel Oral Anticoagulants vs Low Molecular Weight Heparin for Thromboprophylaxis in Large-Volume Liposuction and Body Contouring Procedures. <i>Aesthetic Surgery Journal</i> , 2016, 36, 440-449.	0.9	26
439	Non-Vitamin K Antagonist Oral Anticoagulants. , 2016, , .		1
440	Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population. <i>Cardiology and Therapy</i> , 2016, 5, 19-41.	1.1	51
441	Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 119-127.	1.0	87
442	An evidence summary of the management of patients taking direct oral anticoagulants (DOACs) undergoing dental surgery. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2016, 45, 618-630.	0.7	44
443	Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: Review of the literature and recommendations for specific populations and procedures. <i>International Journal of Cardiology</i> , 2016, 202, 578-585.	0.8	34

#	ARTICLE	IF	CITATIONS
444	Pulmonary Thromboembolism. , 2016, , 1001-1030.e10.		3
445	Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. <i>Europace</i> , 2016, 18, 955-964.	0.7	62
446	Assessment of novel oral anticoagulant use within a community teaching hospital. <i>Saudi Pharmaceutical Journal</i> , 2017, 25, 93-98.	1.2	5
447	Risk of gastrointestinal bleeding with direct oral anticoagulants: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 85-93.	3.7	38
448	2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 69, 871-898.	1.2	342
449	Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 942-948.	1.1	33
450	Economic Evaluations of New Oral Anticoagulants for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement: A Systematic Review. <i>Pharmacoeconomics</i> , 2017, 35, 517-535.	1.7	16
451	Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?. <i>American Journal of Medicine</i> , 2017, 130, 900-906.	0.6	6
452	Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty. <i>Journal of Arthroplasty</i> , 2017, 32, 2911-2919.e6.	1.5	29
453	Risk of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1674-1683.e3.	2.4	109
454	Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-Response Meta-Analysis. <i>Clinical and Translational Science</i> , 2017, 10, 260-270.	1.5	15
455	Fatal pulmonary embolism following elective total knee replacement using aspirin in multi-modal prophylaxis – A 12 year study. <i>Knee</i> , 2017, 24, 1187-1190.	0.8	5
456	Predictive factors for effectiveness and safety of enoxaparin for total knee arthroplasty in aged Japanese patients: a retrospective review. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2017, 3, 6.	0.4	3
457	Perioperative management of patients on direct oral anticoagulants. <i>Thrombosis Journal</i> , 2017, 15, 14.	0.9	92
458	The role of new oral anticoagulants in orthopaedics: an update of recent evidence. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2017, 27, 573-582.	0.6	12
459	Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty. <i>Medicine (United States)</i> , 2017, 96, e8059.	0.4	5
460	Thromboprophylaxis With Apixaban in Patients Undergoing Major Orthopedic Surgery: Meta-Analysis and Trial-Sequential Analysis. <i>Clinical Medicine Insights Blood Disorders</i> , 2017, 10, 1179545X1770466.	0.3	7
461	Deep Venous Thrombosis. <i>Emergency Medicine Clinics of North America</i> , 2017, 35, 743-770.	0.5	74

#	ARTICLE	IF	CITATIONS
462	Comparison of postoperative complications after total hip arthroplasty among patients receiving aspirin, enoxaparin, warfarin, and factor Xa inhibitors. <i>Journal of Orthopaedics</i> , 2017, 14, 537-543.	0.6	29
463	Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis. <i>Cellular Physiology and Biochemistry</i> , 2017, 42, 1999-2020.	1.1	6
464	Persistent Pulmonary Embolism Rates Following Total Knee Arthroplasty Even With Prophylactic Anticoagulants. <i>Journal of Arthroplasty</i> , 2017, 32, 3833-3839.	1.5	28
465	Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2017, 12, 1291-1305.	1.0	23
466	Venous Thromboembolism Prophylaxis in Total Hip Arthroplasty and Total Knee Arthroplasty Patients. <i>Journal of the American Academy of Orthopaedic Surgeons</i> , The, 2017, 25, 789-798.	1.1	46
467	Evaluation of an oral direct factor Xa inhibitor anticoagulant in healthy adult horses. <i>Journal of Veterinary Emergency and Critical Care</i> , 2017, 27, 82-88.	0.4	3
468	Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis. <i>Journal of Arthroplasty</i> , 2017, 32, 645-652.	1.5	53
469	Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition). <i>Regional Anesthesia and Pain Medicine</i> , 2017, 43, 1.	1.1	117
470	Assessment of Patient Adherence to Direct Oral Anticoagulant vs Warfarin Therapy. <i>Journal of Osteopathic Medicine</i> , 2017, 117, 7-15.	0.4	18
471	Quick reference guide to apixaban. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 263-267.	1.0	11
472	Apixaban pharmacodynamic activity in umbilical cord, paediatric, and adult plasma. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1518-1527.	1.8	8
473	Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. <i>Blood Advances</i> , 2017, 1, 1827-1838.	2.5	50
474	The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects. <i>Clinical Pharmacology: Advances and Applications</i> , 2017, Volume 9, 19-28.	0.8	6
475	Asian venous thromboembolism guidelines: updated recommendations for the prevention of venous thromboembolism. <i>International Angiology</i> , 2017, 36, 1-20.	0.4	108
476	Venous Thromboembolism Prophylaxis after Total Knee Arthroplasty. <i>Journal of Knee Surgery</i> , 2018, 31, 605-609.	0.9	6
477	Direct Oral Anticoagulants. , 2018, , 87-103.		0
478	What Surgeons Should Know About Non-Vitamin K Oral Anticoagulants. <i>JAMA Surgery</i> , 2018, 153, 577.	2.2	29
479	Cardiovascular Drugs and Hemostasis. , 2018, , 561-589.		0

#	ARTICLE	IF	CITATIONS
480	The role of extended venous thromboembolism prophylaxis following urologic pelvic surgery. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 83-87.	0.8	6
481	Extended Venous Thromboembolism Prophylaxis after Radical Cystectomy: A Call for Adherence to Current Guidelines. <i>Journal of Urology</i> , 2018, 199, 906-914.	0.2	22
482	Anticoagulantes orales directos: puesta al día. <i>Medicina Clínica</i> , 2018, 151, 198-206.	0.3	23
483	Management of Direct-Acting Oral Anticoagulants Surrounding Dental Procedures With Low-to-Moderate Risk of Bleeding. <i>Journal of Pharmacy Practice</i> , 2018, 31, 202-207.	0.5	15
484	European guidelines on perioperative venous thromboembolism prophylaxis. <i>European Journal of Anaesthesiology</i> , 2018, 35, 96-107.	0.7	15
485	Antithrombotic Stewardship: Assessing Use of Computerized Clinical Decision Support Tools to Enhance Safe Prescribing of Direct Oral Anticoagulants in Hospitalized Patients. <i>Journal of Patient Safety</i> , 2021, 17, e1057-e1061.	0.7	6
486	A Case of a Reversible Neurologic Adverse Reaction to Apixaban Confirmed by Re-Challenge. <i>Journal of Clinical Medicine Research</i> , 2018, 10, 523-526.	0.6	6
487	Safety of In-Hospital Only Thromboprophylaxis after Fast-Track Total Hip and Knee Arthroplasty: A Prospective Follow-Up Study in 17,582 Procedures. <i>Thrombosis and Haemostasis</i> , 2018, 118, 2152-2161.	1.8	55
488	A Review of the Efficacy and Safety Profiles of the Novel Oral Anticoagulants in the Treatment and Prevention of Venous Thromboembolism. <i>Clinical Therapeutics</i> , 2018, 40, 2140-2167.	1.1	15
489	Venous thromboembolism after total joint arthroplasty: Risk stratification and prophylaxis. <i>Seminars in Arthroplasty</i> , 2018, 29, 200-204.	0.3	1
490	Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 728-738.	1.3	49
491	Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2018, 12, 361-380.	1.0	17
492	Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: a meta-analysis. <i>Bioscience Reports</i> , 2018, 38, .	1.1	8
493	Pulmonary Embolism While on Aspirin for Venous Thromboembolism Prophylaxis After Total Knee Arthroplasty. <i>Journal of Primary Care and Community Health</i> , 2018, 9, 215013271879744.	1.0	0
494	Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis. <i>BMC Musculoskeletal Disorders</i> , 2018, 19, 322.	0.8	20
495	Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives. <i>Personalized Medicine</i> , 2018, 15, 209-221.	0.8	22
496	Patient Safety Issues. <i>Advances in Cosmetic Surgery</i> , 2018, 1, 219-229.	0.4	0
497	Direct oral anticoagulants: An update. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 198-206.	0.1	15

#	ARTICLE	IF	CITATIONS
498	Thromboembolism prophylaxis in orthopaedics: an update. EFORT Open Reviews, 2018, 3, 136-148.	1.8	142
499	Edoxaban Enhances Thromboprophylaxis by Physiotherapy After Total Knee Arthroplastyâ€• The Randomized Controlled ESCORT-TKA Trial â€•. Circulation Journal, 2018, 82, 524-531.	0.7	5
500	Meta-Analysis Comparing the Efficacy, Safety, and Cost-Benefit of Direct Acting Oral Anticoagulants Versus Enoxaparin Thromboprophylaxis to Prevent Venous Thromboembolism Among Hospitalized Patients. American Journal of Cardiology, 2018, 122, 1236-1243.	0.7	7
501	A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents. Journal of Clinical Medicine, 2018, 7, 29.	1.0	29
502	Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacological Research, 2018, 135, 60-79.	3.1	81
503	Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban, Enoxaparin, or Aspirin for Thromboprophylaxis. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 1315-1321.	0.7	33
504	Risk of Venous Thromboembolism in Surgical Elderly Patients. , 2018, , 65-78.		0
505	Low molecular weight heparin for the prevention of deep venous thrombosis after total knee arthroplasty: A systematic review and meta-analysis. International Journal of Surgery, 2018, 54, 265-275.	1.1	10
506	Direct-Acting Oral Anticoagulants in Critically Ill Patients. Chest, 2019, 156, 604-618.	0.4	11
507	Population Pharmacokinetics and Pharmacodynamics of Apixaban Linking Its Plasma Concentration to Intrinsic Activated Coagulation Factor X Activity in Japanese Patients with Atrial Fibrillation. AAPS Journal, 2019, 21, 80.	2.2	4
508	Direct-Acting Oral Anticoagulants and Their Reversal Agentsâ€• An Update. Medicines (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 342	0.7	31
509	Risk of Pulmonary Embolism More Than 6 Weeks After Surgery Among Cancer-Free Middle-aged Patients. JAMA Surgery, 2019, 154, 1126.	2.2	23
510	Fifty years of research on antithrombotic therapy: Achievements and disappointments. European Journal of Internal Medicine, 2019, 70, 1-7.	1.0	17
511	<p>Differences In Gastrointestinal Safety Profiles Among Novel Oral Anticoagulants: Evidence From A Network Meta-Analysis<p>. Clinical Epidemiology, 2019, Volume 11, 911-921.	1.5	27
512	Randomized phase 2 trial comparing JNJâ€•375, a thrombinâ€•directed antibody, with apixaban for prevention of venous thrombosis. Journal of Thrombosis and Haemostasis, 2019, 17, 2081-2088.	1.9	4
513	Venous thromboembolism in plastic surgery: the current state of evidence in risk assessment and chemoprophylactic options. Journal of Plastic Surgery and Hand Surgery, 2019, 53, 370-380.	0.4	3
514	Venous thromboembolism prophylaxis strategies for people undergoing elective total knee replacement: a systematic review and network meta-analysis. Lancet Haematology,the, 2019, 6, e530-e539.	2.2	23
515	Interaction Between Direct Factor Xa Inhibitors and Digoxin. American Journal of Therapeutics, 2019, 26, e649-e652.	0.5	1

#	ARTICLE	IF	CITATIONS
516	Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis. <i>Journal of Arthroplasty</i> , 2019, 34, 789-800.e6.	1.5	13
517	Venous Thromboembolism Chemoprophylaxis in Total Hip and Knee Arthroplasty. <i>JBJS Reviews</i> , 2019, 7, e2-e2.	0.8	6
518	O que mudou nas últimas décadas na profilaxia do tromboembolismo venoso em pacientes internados: artigo de revisão. <i>Jornal Vascular Brasileiro</i> , 2019, 18, e20180021.	0.1	5
519	Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1265-1279.	1.6	174
520	Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 439-453.	1.0	20
521	Direct oral anticoagulants versus aspirin for venous thromboembolism prophylaxis after orthopedic surgery. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, S55-S60.	0.5	4
522	The Effects of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Volunteers: A Single-Sequence Crossover Study. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 561-567.	1.0	9
523	Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelatx, a phase 2 pilot study. <i>American Journal of Hematology</i> , 2019, 94, 635-640.	2.0	43
524	PREVAPIX-ALL: Apixaban Compared to Standard of Care for Prevention of Venous Thrombosis in Paediatric Acute Lymphoblastic Leukaemia (ALL) – Rationale and Design. <i>Thrombosis and Haemostasis</i> , 2019, 119, 844-853.	1.8	49
525	Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 45.	1.3	22
526	Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 525-539.	1.0	8
527	Use of modified intention-to-treat analysis in studies of direct oral anticoagulants and risk of selection bias: a systematic review. <i>BMJ Evidence-Based Medicine</i> , 2019, 24, 63-69.	1.7	1
528	American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. <i>Blood Advances</i> , 2019, 3, 3898-3944.	2.5	299
529	Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study. <i>Pharmacological Research</i> , 2019, 141, 201-207.	3.1	11
530	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section – Special Situations. <i>Thrombosis and Haemostasis</i> , 2019, 119, 014-038.	1.8	28
531	Outpatient Oral Anticoagulant Therapy. , 2019, , 747-777.		1
532	Preventive Effects of Different Drugs on Asymptomatic Lower Extremities Deep Venous Thrombosis After Artificial Joint Replacement: A Mixed Treatment Comparison. <i>American Journal of Therapeutics</i> , 2019, 26, e45-e53.	0.5	5
533	Venous Thromboembolism in Neurocritical Care Patients. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 1226-1234.	1.3	9

#	ARTICLE	IF	CITATIONS
534	Does the use of postoperative low-molecular-weight heparin in patients with lung cancer increase tube drainage?. <i>Asian Journal of Surgery</i> , 2020, 43, 278-281.	0.2	3
535	Dental Implant Treatment in Medically Compromised Patients. , 2020, , .		1
536	Stabilityâ€indicating RPâ€HPLC method development and validation for determination of nine impurities in apixaban tablet dosage forms. Robustness study by quality by design approach. <i>Biomedical Chromatography</i> , 2020, 34, e4719.	0.8	31
537	Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 792-799.e61.	2.4	54
538	Superiority Versus Noninferiority. <i>Foot and Ankle International</i> , 2020, 41, 624-625.	1.1	0
539	American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. <i>Blood Advances</i> , 2020, 4, 4693-4738.	2.5	636
540	Cost-effectiveness of apixaban for prevention of venous thromboembolic events in patients after gynecologic cancer surgery. <i>Gynecologic Oncology</i> , 2020, 159, 476-482.	0.6	11
542	A Prospective Cohort Comparative Study of Rivaroxaban, Dabigatran, and Apixaban Oral Thromboprophylaxis in 2431 Hip and Knee Arthroplasty Patients: Primary Efficacy Outcomes and Safety Profile. <i>Journal of Arthroplasty</i> , 2020, 35, 3093-3098.	1.5	13
543	Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm. <i>JAMA Network Open</i> , 2020, 3, e207410.	2.8	68
544	Evaluation of oral factor Xa inhibitorâ€associated extracranial bleeding reversal with andexanet alfa. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2532-2541.	1.9	20
545	Prevention, diagnosis, and management of venous thromboembolism in the critically ill surgical and trauma patient. <i>Current Opinion in Critical Care</i> , 2020, 26, 640-647.	1.6	10
546	Drug interactions with apixaban: A systematic review of the literature and an analysis of Vigibase, the World Health Organization database of spontaneous safety reports. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00647.	1.1	21
547	Association Between Nonvitamin K Antagonist Oral Anticoagulants or Warfarin and Liver Injury: A Cohort Study. <i>American Journal of Gastroenterology</i> , 2020, 115, 1513-1524.	0.2	9
548	Updates on the use of direct oral anticoagulants for the management of chronic conditions. <i>Pharmacy Today</i> , 2020, 26, 44-58.	0.0	0
549	A matter of time: duration and choice of venous thromboprophylaxis in patients diagnosed with COVID-19. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2020, 81, 1-2.	0.2	5
550	Apixaban (I) in several aqueous co-solvent mixtures: Solubility, solvent effect and preferential solvation. <i>Journal of Chemical Thermodynamics</i> , 2020, 150, 106200.	1.0	4
551	SBA 2020: Regional anesthesia guideline for using anticoagulants update. <i>Brazilian Journal of Anesthesiology (Elsevier)</i> , 2020, 70, 364-387.	0.2	1
552	Temporal trends in pharmacologic prophylaxis for venous thromboembolism after hip and knee replacement in older adults. <i>Vascular Medicine</i> , 2020, 25, 450-459.	0.8	2

#	ARTICLE	IF	CITATIONS
553	Chinese Survey on Enhanced Recovery after Surgery and Thromboprophylaxis Following Arthroplasty. <i>Orthopaedic Surgery</i> , 2020, 12, 900-906.	0.7	6
555	Prevention of thrombosis. , 2020, , 59-104.		0
556	Direct Oral Anticoagulants in the Prevention of Venous Thromboembolism Following Surgery for Hip Fracture in Older Adults: A Population-Based Cohort Study. <i>Geriatric Orthopaedic Surgery and Rehabilitation</i> , 2020, 11, 215145931989752.	0.6	10
557	Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 130.	3.8	146
558	Prise en charge d'une allergie à la parine: un case report et une revue de la littérature. <i>Revue Française D'allergologie</i> , 2020, 60, 170-174.	0.1	0
559	The use of direct oral anticoagulants in patients with ventricular assist devices: Is there hope for Factor Xa inhibition?. <i>Artificial Organs</i> , 2021, 45, E123-E129.	1.0	6
560	Direct oral anticoagulant use in gynecologic oncology: A Society of Gynecologic Oncology Clinical Practice Statement. <i>Gynecologic Oncology</i> , 2021, 160, 312-321.	0.6	15
561	Direct oral anticoagulants (DOACs) and neck of femur fractures: Standardising the perioperative management and time to surgery. <i>Journal of Clinical Orthopaedics and Trauma</i> , 2021, 12, 138-147.	0.6	7
562	Risque thromboembolique veineux chez les patients traumatisés d'un membre inférieur nécessitant une immobilisation : vers une approche individualisée. <i>Annales Françaises De Médecine D'Urgence</i> , 2021, 11, 311-319.	0.0	0
563	Major gastrointestinal bleeding risk with direct oral anticoagulants: Does type and dose matter? A systematic review and network meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e50-e58.	0.8	25
564	Risk of intracranial hemorrhage with direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Neurology</i> , 2022, 269, 664-675.	1.8	14
565	Initial Experience with Apixaban for Extended Venous Thromboembolism Prophylaxis After Radical Cystectomy. <i>European Urology Focus</i> , 2022, 8, 480-482.	1.6	3
566	The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants. <i>Medicine (United States)</i> , 2021, 100, e25216.	0.4	10
567	Safety and Efficacy of Rivaroxaban and Apixaban in Patients with Increased Body Mass: a Systematic Review. <i>Clinical Drug Investigation</i> , 2021, 41, 353-369.	1.1	9
568	Comparative risk for intracranial hemorrhage related to new oral anticoagulants. <i>Medicine (United States)</i> , 2021, 100, e25216.	0.4	1
569	Venous thromboembolism prophylaxis in high-risk orthopedic and cancer surgery. <i>Postgraduate Medicine</i> , 2021, 133, 20-26.	0.9	7
570	Thromboprophylaxis for orthopedic surgery; An updated meta-analysis. <i>Thrombosis Research</i> , 2021, 199, 43-53.	0.8	7
571	Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis. <i>Pharmacological Research</i> , 2021, 166, 105438.	3.1	9

#	ARTICLE	IF	CITATIONS
573	Safety and Effectiveness of Apixaban in Japanese Patients With Venous Thromboembolism in Clinical Practice—A Post-Marketing Surveillance. <i>Circulation Journal</i> , 2021, 85, 2201-2207.	0.7	5
574	Are the correct outcomes being measured in studies of oral anticoagulants? A systematic survey. <i>Thrombosis Research</i> , 2021, 201, 30-49.	0.8	3
575	Efficacy and safety of anticoagulants for postoperative thromboprophylaxis in total hip and knee arthroplasty: A PRISMA-compliant Bayesian network meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0250096.	1.1	8
576	APIXABAN OR ENOXAPARIN: WHICH IS BETTER FOR THROMBOPROPHYLAXIS AFTER TOTAL HIP AND TOTAL KNEE ARTHROPLASTY IN INDIAN PATIENTS?. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	0
577	Effectiveness of apixaban versus enoxaparin in preventing wound complications and deep venous thrombosis following total knee replacement surgery: A retrospective study. <i>International Journal of Clinical Practice</i> , 2021, 75, e14552.	0.8	0
578	Venous Thromboembolic Prophylaxis After Total Hip and Knee Arthroplasty. <i>Journal of Bone and Joint Surgery - Series A</i> , 2021, 103, 1556-1564.	1.4	15
579	Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 974-984.	0.8	3
580	Wound complications and bleeding with new oral anticoagulants in patients undergoing total joint arthroplasty: A systematic review and meta-analysis of randomized controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	1
581	Asia-Pacific venous thromboembolism consensus in knee and hip arthroplasty and hip fracture surgery: Part 3. Pharmacological venous thromboembolism prophylaxis. <i>Knee Surgery and Related Research</i> , 2021, 33, 24.	1.8	11
582	Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment. <i>Drugs in R and D</i> , 2021, 21, 375-384.	1.1	6
583	A Review of Current and Future Antithrombotic Strategies in Surgical Patients—Leaving the Graduated Compression Stockings Behind?. <i>Journal of Clinical Medicine</i> , 2021, 10, 4294.	1.0	5
584	Thromboembolic and bleeding complications following primary total knee arthroplasty. <i>Bone and Joint Journal</i> , 2021, 103-B, 1571-1577.	1.9	3
585	A risk-stratified approach to venous thromboembolism prophylaxis with aspirin or warfarin following total hip and knee arthroplasty: A cohort study. <i>Thrombosis Research</i> , 2021, 206, 120-127.	0.8	3
586	Cardiovascular Drugs and Hemostasis. , 2022, , 701-729.		1
587	New Drugs for Thromboprophylaxis: Apixaban, Dabigatran, Rivaroxaban. , 2013, , 67-79.		1
588	Venous Thromboembolism Prophylaxis in the Patient with Rheumatic Diseases Undergoing Orthopedic Surgery. , 2013, , 45-56.		1
590	Drug-Induced Disorders and Dental Implant Treatment. , 2020, , 149-183.		2
591	Neue Arzneimittel 2011. , 2012, , 43-126.		1

#	ARTICLE	IF	CITATIONS
592	Prevention of Cardiovascular Disease in Older Adults. , 2015, , 1763-1786.		1
593	Prediction of Symptomatic Venous Thromboembolism in Critically Ill Patients: The ICU-Venous Thromboembolism Score*. Critical Care Medicine, 2020, 48, e470-e479.	0.4	19
595	Novos anticoagulantes para a profilaxia do tromboembolismo venoso em cirurgias ortopédicas de grande porte. Jornal Vascular Brasileiro, 2011, 10, 145-153.	0.1	9
596	Pharmacokinetics and Pharmacogenetics of Apixaban. Rational Pharmacotherapy in Cardiology, 2020, 16, 852-860.	0.3	5
597	ORAL ANTICOAGULANTS IN THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS: FOCUS ON APIXABAN. Meditsinskiy Sovet, 2017, , 56-62.	0.1	2
598	Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban. Current Cardiology Reviews, 2016, 13, 41-46.	0.6	4
599	The evolution of anticoagulant therapy. Blood Transfusion, 2016, 14, 175-84.	0.3	53
600	Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults. Blood Transfusion, 2016, 14, 23-65.	0.3	78
601	Graduated compression stockings for the prevention of deep-vein thrombosis in postoperative surgical patients: a systematic review and economic model with a value of information analysis. Health Technology Assessment, 2015, 19, 1-220.	1.3	26
602	Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technology Assessment, 2017, 21, 1-386.	1.3	117
603	Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation. Health Technology Assessment, 2019, 23, 1-190.	1.3	17
605	New Oral Antithrombotic Agents for the Prevention of Deep Venous Thrombosis and Pulmonary Embolism in Orthopedic Surgery. Orthopedics, 2010, 33, 27-32.	0.5	2
606	Never Events and Related Quality Measures Following Total Hip and Total Knee Replacement. Orthopedics, 2010, 33, 838-842.	0.5	7
607	Novel Oral Anticoagulants for VTE Prevention in Orthopedic Surgery: Overview of Phase 3 Trials. Orthopedics, 2011, 34, 795-804.	0.5	14
608	Nuevos anticoagulantes orales. Revista Medica De Chile, 2011, 139, 1347-1355.	0.1	8
609	Oral and parenteral anticoagulants. Journal of Postgraduate Medicine, 2012, 58, 275-285.	0.2	10
610	Clinical and pharmacological properties of new oral anticoagulants for the prevention of cerebral thromboembolism: Factor Xa and thrombin inhibitors. World Journal of Neuroscience, 2012, 02, 7-14.	0.1	4
611	Anticoagulant treatment: the end of the old agents?. Swiss Medical Weekly, 2012, 142, w13684.	0.8	6

#	ARTICLE	IF	CITATIONS
612	Direct oral anticoagulants: a guide for daily practice. Swiss Medical Weekly, 2016, 146, w14286.	0.8	11
613	A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?. Anatolian Journal of Cardiology, 2015, 15, 1020-1029.	0.5	20
614	Recent Progress in Antithrombotic Therapy for Atrial Fibrillation. Journal of Atherosclerosis and Thrombosis, 2011, 18, 257-273.	0.9	3
616	Anticoagulation: Where have we come from and where are we going? The evidence for and against novel anticoagulants. South African Medical Journal, 2014, 104, 143.	0.2	1
617	Safety of apixaban in Indian patients undergoing elective total knee replacement or total hip replacement surgery: A multi-center, phase-IV study. SAGE Open Medicine, 2021, 9, 205031212110499.	0.7	0
618	Reversal Activity and Toxicity of Heparin-Binding Copolymer after Subcutaneous Administration of Enoxaparin in Mice. International Journal of Molecular Sciences, 2021, 22, 11149.	1.8	1
620	Thrombocytopenia Due to Direct Oral Anticoagulation and Low-Molecular-Weight Heparin. Cureus, 2021, 13, e18757.	0.2	1
621	Dabigatran: ready for prime time?. Polish Archives of Internal Medicine, 2010, 120, 137-142.	0.3	2
622	Post-operative thromboprophylaxis: new oral thrombin and factor X inhibitors and their place in clinical practice. F1000 Medicine Reports, 2010, 2, .	2.9	0
623	New anticoagulant commentary from a basic viewpoint. Japanese Journal of Thrombosis and Hemostasis, 2011, 22, 151-155.	0.1	0
627	Prevention of venous thromboembolism (VTE) in ICU: an overview of newly developed anticoagulants. Journal of the Japanese Society of Intensive Care Medicine, 2012, 19, 177-184.	0.0	0
628	Apixaban for the Prevention of Thromboembolism in Adults after Elective Hip or Knee Replacement Surgery, and in Symptomatic Venous Thromboembolism. Clinical Medicine Reviews in Vascular Health, 0, 4, 19-28.	3.0	0
630	Update on thromboprophylaxis in orthopedic surgery and critical appraisal of the role of enoxaparin. Orthopedic Research and Reviews, 0, , 33.	0.7	0
631	Thromboprophylaxis in High-Risk Orthopedic Surgery: Total Hip and Knee Arthroplasty and Hip Fracture. , 2013, , 113-121.		0
635	New Oral Anticoagulants. , 2013, , 53-86.		0
636	Idiopathic Venous Thromboembolism. , 2013, , 153-174.		0
637	Detection and Management of Atrial Fibrillation in Patients with Stroke or TIA in Clinical Practice. , 2014, , 221-236.		0
638	Newer Oral Anticoagulants. , 2014, , 237-248.		0

#	ARTICLE	IF	CITATIONS
639	The new oral anticoagulants in clinical practice. Revista Médica De Minas Gerais, 2014, 24, .	0.0	1
640	Prevention of Cardiovascular Disease in Older Adults. , 2014, , 1-28.		0
641	Novel oral anticoagulant medications: Impact of pharmacodynamic mechanisms on the efficacy and safety. Srce I Krvni Sudovi, 2014, 33, 188-191.	0.1	0
642	Pharmacological Treatment of Venous Disorders. , 2014, , 1-29.		0
643	Emergent Reversal of Oral Anticoagulation: Review of Current Treatment Strategies. AACN Advanced Critical Care, 2014, 25, 5-12.	0.6	0
644	Rapport sur les anticoagulants oraux directs (AOD) (anticoagulation dite « nouvelle ») Tj ETQq1 1 0.784314 rgBT /Oylock 10	0.0	0
645	TEG ir naujieji peroraliniai antikoagulantai. Health Sciences, 2014, 24, 72-77.	0.0	0
646	Prevention of Venous Thromboembolism. , 2015, , 127-149.		0
647	Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban. Cardiology Research, 2015, 6, 267-277.	0.5	1
648	Novel Oral Anticoagulants for Stroke Prophylaxis and Venous Thromboembolism Prevention and Treatment. Journal of Patient-centered Research and Reviews, 2015, 2, 139-146.	0.6	1
649	Factor Xa Inhibitors. , 2016, , 25-71.		1
650	Thromboprophylaxis in Orthopedic Surgery. , 2016, , 33-46.		0
651	Research Progress of Prevention and Control of Deep Vein Thrombosis Embolism. Hans Journal of Surgery, 2017, 06, 13-20.	0.0	0
652	Overview of the Direct Oral Anticoagulants. Journal of the Minneapolis Heart Institute Foundation, 2017, 1, 38-58.	0.0	1
653	Direct-acting oral anticoagulants: An overview. Saudi Journal of Medicine and Medical Sciences, 2017, 5, 210.	0.3	0
654	ORAL ANTICOAGULANTS IN THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS: FOCUS ON APIXABAN. Meditsinskiy Sovet, 2017, , 56-62.	0.1	0
655	Study of rivaroxaban for venous thromboembolism prophylaxis after lower extremity fractures in Russian clinical practice. N N Priorov Journal of Traumatology and Orthopedics, 2018, 25, 47-51.	0.1	0
656	Clinical and Economic Outcomes of New Oral Anticoagulants in Orthopaedics. Serbian Journal of Experimental and Clinical Research, 2018, 19, 3-9.	0.2	0

#	ARTICLE	IF	CITATIONS
657	STUDY OF RIVAROXABAN FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS AFTER LOWER EXTREMITY FRACTURES IN RUSSIAN CLINICAL PRACTICE. N N Priorov Journal of Traumatology and Orthopedics, 2018, , 47-51.	0.1	0
659	Application of a new peroral anticoagulants in treatment and prophylaxis of thromboembolic complications. Klinichna Khirurgiia, 2019, 86, 73-76.	0.0	1
660	Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation. Journal of Stroke, 2019, 21, 259-275.	1.4	6
661	Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia. American Journal of Case Reports, 2020, 21, e922498.	0.3	2
662	The Prevention of Venous Thromboembolism in Surgical Patients. Advances in Experimental Medicine and Biology, 2016, , .	0.8	0
663	New options in anticoagulation for the prevention of venous thromboembolism and stroke. P and T, 2011, 36, 86-99.	1.0	5
664	Novel oral anticoagulants for venous thromboembolism prophylaxis after total hip or knee replacement: an update on rivaroxaban (xarelto). P and T, 2013, 38, 45-50.	1.0	1
665	Role of apixaban (eliquis) in the treatment and prevention of thromboembolic disease. P and T, 2013, 38, 206-31.	1.0	8
666	Benefits of novel oral anticoagulant agents for thromboprophylaxis after total hip or knee arthroplasty. American Health and Drug Benefits, 2012, 5, 115-22.	0.5	3
667	Thromboprophylaxis and orthopaedic surgery: options and current guidelines. The Malaysian Journal of Medical Sciences, 2014, 21, 71-7.	0.3	6
668	Use of direct oral anticoagulants in daily practice. American Journal of Blood Research, 2018, 8, 57-72.	0.6	18
669	Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates in patients after hip or knee replacement surgery. Blood Transfusion, 2019, 17, 157-162.	0.3	4
670	Efficacy and Safety of Thromboprophylaxis Post-Orthopedic Surgery. Cureus, 2021, 13, e19691.	0.2	3
671	Direct Oral Anticoagulants: A Review for the Non-Specialist. Hematology Reports, 2021, 13, 9239.	0.3	2
672	Enoxaparin versus Direct Oral Anticoagulants for Venous Thromboembolism in Asians Undergoing Total Knee Arthroplasty: A Meta-Analysis and Systematic Review. Journal of Arthroplasty, 2021, , .	1.5	1
673	Assessment of Antiâ€œa activity in patients receiving concomitant apixaban with strong pâ€œglycoprotein inhibitors and statins. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 668-675.	0.7	6
674	New Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Total Hip and Knee Arthroplasty: A Systematic Review and Network Meta-Analysis. Frontiers in Pharmacology, 2021, 12, 775126.	1.6	6
675	Aspirin thromboprophylaxis in joint replacement surgery. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12649.	1.0	1

#	ARTICLE	IF	CITATIONS
676	Recommendations from the ICM-VTE: Hip & Knee. Journal of Bone and Joint Surgery - Series A, 2022, 104, 180-231.	1.4	28
677	Editor's Choice " Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials. European Journal of Vascular and Endovascular Surgery, 2022, 63, 465-474.	0.8	4
678	Recommendations from the ICM-VTE: General. Journal of Bone and Joint Surgery - Series A, 2022, 104, 4-162.	1.4	14
679	Global Research Status and Trends in Venous Thromboembolism After Hip or Knee Arthroplasty From 1990 to 2021: A Bibliometric Analysis. Frontiers in Medicine, 2022, 9, 837163.	1.2	3
680	Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020. BMJ Open, 2022, 12, e058279.	0.8	4
682	Prophylaxis for Venous Thromboembolic Events in Elective Total Hip and Total Knee Arthroplasty. Current Pharmaceutical Design, 2022, 28, 771-777.	0.9	4
683	Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis. European Cardiology Review, 0, 17, .	0.7	3
684	Anticoagulants: dose control methods and inhibitors. Obstetrics, Gynecology and Reproduction, 2022, 16, 158-175.	0.2	2
685	Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data. American Journal of Cardiovascular Drugs, 2022, 22, 615-631.	1.0	8
686	Identification, Isolation, and Structural Characterization of Novel Forced Degradation Products of Apixaban Using Advanced Analytical Techniques Like Uplc-Ms, Prep-Hplc, Hrms, Ft-Ir, and 2d-Nmr. SSRN Electronic Journal, 0, , .	0.4	0
687	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. JAMA Cardiology, 2022, 7, 747.	3.0	15
689	Are outpatient anticoagulation management services the wave of the future (again)?. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	1.0	1
690	Which Are the Best Techniques for Reducing the Incidence of Postoperative Deep Vein Thrombosis?. , 2023, , 407-416.		0
691	Risk of nonmajor bleeding upon use of direct oral anticoagulants for preventing and treating venous thromboembolism: A network meta-analysis. Vascular Medicine, 0, , 1358863X2211152.	0.8	0
692	Thromboprophylaxis in Urological and Andrological Surgery (Review article). Health of Man, 2022, , 74-79.	0.1	0
693	Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery"Systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 2022, 20, 2930-2938.	1.9	16
694	Consensus Recommendations for Preventing and Managing Bleeding Complications Associated with Novel Oral Anticoagulants in Singapore. Annals of the Academy of Medicine, Singapore, 2013, 42, 593-602.	0.2	3
695	Minimisation of Bleeding Risks Due to Direct Oral Anticoagulants. European Medical Journal Hematology, 0, , 78-90.	0.0	0

#	ARTICLE	IF	CITATIONS
696	Re: Do no harm: the role of perioperative heparin in urethroplasty. Lee et al. IJUN (2022). International Urology and Nephrology, 0, , .	0.6	0
697	Joint 2022 European Society of Thoracic Surgeons and The American Association for Thoracic Surgery guidelines for the prevention of cancer-associated venous thromboembolism in thoracic surgery. European Journal of Cardio-thoracic Surgery, 2022, 63, .	0.6	6
698	Joint 2022 European Society of Thoracic Surgeons and The American Association for Thoracic Surgery guidelines for the prevention of cancer-associated venous thromboembolism in thoracic surgery. Journal of Thoracic and Cardiovascular Surgery, 2022, , .	0.4	2
699	Clinical Studies with Anticoagulants that Have Changed Clinical Practice. Seminars in Thrombosis and Hemostasis, 2023, 49, 242-254.	1.5	4
700	Which Are the Best Techniques for Reducing the Incidence of Postoperative Deep Vein Thrombosis?. , 2013, , 275-282.		0
701	Apixaban for extended postoperative thromboprophylaxis in gynecologic oncology patients undergoing laparotomy. Gynecologic Oncology, 2023, 172, 9-14.	0.6	3
702	Statistical Fragility of Venous Thromboembolism Prophylaxis Following Total Joint Arthroplasty. Arthroplasty Today, 2023, 20, 101111.	0.8	0
703	Hematology and Coagulation. , 2013, , 131-147.e6.		0
705	Optimization for small volume of distribution leading to the discovery of apixaban. , 2023, , 123-135.		0
713	FactorÂI Inhibitors: A New Horizon in Anticoagulation Therapy. Cardiology and Therapy, 2024, 13, 1-16.	1.1	0